Reverse genetics to develop a second generation Rift Valley fever vaccine

逆向遗传学开发第二代裂谷热疫苗

基本信息

  • 批准号:
    8389649
  • 负责人:
  • 金额:
    $ 35.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-12-15 至 2015-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Rift Valley fever virus (RVFV), which belongs to the genus Phlebovirus, family Bunyaviridae, is one of the most important emerging viruses. It is listed as an NIAID category A pathogen. RVFV is transmitted by mosquitoes and causes severe disease in both humans and livestock. A proportion of infected humans develop hemorrhagic fever, encephalitis or retinal vasculitis; the offspring of infected ruminants often die in utero. RVFV is endemic in sub-Saharan African countries, but other countries are preparing for potential introductions of RVFV due to climate change, air transport, and/or bioterrorism. The only truly effective countermeasure is vaccination. RVFV has a tripartite negative-stranded RNA genome composed of the S-, M- and L-segments. The genome encodes 4 major structural proteins (N, Gn, Gc and L), 2 nonstructural proteins (NSs and NSm) and a 78-kD protein whose function is poorly characterized. A candidate live-attenuated vaccine, MP-12, was developed by 12 serial passages of the wild-type ZH548 strain in human diploid MRC-5 cells in the presence of a chemical mutagen. Our preliminary data in the mouse model suggest that MP-12 is attenuated by the combined effect of partially attenuated M- and L-segments. The current MP-12 vaccine poses a significant risk for use in humans because attenuation of the virus is not complete, and reversion of either the M- or L- segment could potentially increase the virulence of MP-12. Therefore, it is essential to characterize the mechanism of MP-12 attenuation to further improve its safety. My long term goal is to establish effective countermeasures against highly virulent negative-stranded RNA viruses, with special emphasis on vaccination. The central hypothesis is that the current candidate MP-12 vaccine can be further improved for safety by introducing mutations into either the S- or M-segment by reverse genetics while retaining immunogenicity. The overall objective is to characterize existing attenuation mutations in the MP-12 genome, and improve the safety of MP-12 by incorporating further attenuation mutations into the S- or M-segment. The three specific aims are proposed as follows: Specific Aim 1: To identify and characterize attenuation mutations of MP-12, Specific Aim 2: To attenuate the MP-12 S-segment without reducing the immunogenicity of MP-12, and Specific Aim 3: To attenuate the MP-12 M-segment by modifying the cytoplasmic domains of Gn or Gc. The proposed study will harness the advantage of using of reverse genetics for vaccine development, and develop a next generation of live-attenuated RVFV vaccine candidates that are highly immunogenic and very safe.
描述(由申请人提供):裂谷热病毒(RVFV)属于布尼亚病毒科白蛉病毒属,是最重要的新兴病毒之一。它被列为NIAID A类病原体。RVFV由蚊子传播,并在人类和牲畜中引起严重疾病。一部分受感染的人会发展为出血热、脑炎或视网膜血管炎;受感染的反刍动物的后代通常在子宫内死亡。RVFV在撒哈拉以南非洲国家流行,但其他国家正在准备由于气候变化,航空运输和/或生物恐怖主义而引入RVFV。唯一有效的预防措施是接种疫苗。 RVFV具有由S-、M-和L-区段组成的三重负链RNA基因组。该基因组编码4种主要结构蛋白(N、Gn、Gc和L)、2种非结构蛋白(NS和NSm)和一种78 kD的蛋白,该蛋白的功能尚不清楚。通过在存在化学诱变剂的情况下将野生型ZH 548株在人二倍体MRC-5细胞中连续传代12次,开发了候选减毒活疫苗MP-12。我们在小鼠模型中的初步数据表明,MP-12通过部分减毒的M-和L-节段的联合作用而减毒。目前的MP-12疫苗在人类中使用时具有显著的风险,因为病毒的减毒不完全,M-或L-片段的回复突变可能会增加MP-12的毒力。因此,必须表征MP-12衰减的机制,以进一步提高其安全性。 我的长期目标是建立有效的对抗高毒力负链RNA病毒的对策,特别强调疫苗接种。中心假设是,通过反向遗传学将突变引入S-或M-片段,同时保留免疫原性,可以进一步改善当前候选MP-12疫苗的安全性。总体目标是表征MP-12基因组中现有的减毒突变,并通过将进一步的减毒突变并入S-或M-片段中来提高MP-12的安全性。提出的三个具体目标如下:具体目标1:鉴定和表征MP-12的减毒突变,具体目标2:在不降低MP-12免疫原性的情况下减毒MP-12 S-片段,具体目标3:通过修饰Gn或Gc的胞质结构域来减毒MP-12 M-片段。这项拟议的研究将利用反向遗传学用于疫苗开发的优势,并开发下一代具有高度免疫原性和非常安全的RVFV减毒活疫苗候选物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tetsuro Ikegami其他文献

Tetsuro Ikegami的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tetsuro Ikegami', 18)}}的其他基金

Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1
新型裂谷热候选疫苗 RVax-1 的安全性和免疫原性
  • 批准号:
    10353404
  • 财政年份:
    2020
  • 资助金额:
    $ 35.96万
  • 项目类别:
Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1
新型裂谷热候选疫苗 RVax-1 的安全性和免疫原性
  • 批准号:
    10578688
  • 财政年份:
    2020
  • 资助金额:
    $ 35.96万
  • 项目类别:
Reverse genetics to develop a second generation Rift Valley fever vaccine
逆向遗传学开发第二代裂谷热疫苗
  • 批准号:
    8206484
  • 财政年份:
    2010
  • 资助金额:
    $ 35.96万
  • 项目类别:
Reverse genetics to develop a second generation Rift Valley fever vaccine
逆向遗传学开发第二代裂谷热疫苗
  • 批准号:
    8585809
  • 财政年份:
    2010
  • 资助金额:
    $ 35.96万
  • 项目类别:
Reverse genetics to develop a second generation Rift Valley fever vaccine
逆向遗传学开发第二代裂谷热疫苗
  • 批准号:
    8025374
  • 财政年份:
    2010
  • 资助金额:
    $ 35.96万
  • 项目类别:

相似国自然基金

湍流和化学交互作用对H2-Air-H2O微混燃烧中NO生成的影响研究
  • 批准号:
    51976048
  • 批准年份:
    2019
  • 资助金额:
    61.0 万元
  • 项目类别:
    面上项目

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    Standard Grant
SBIR Phase I: High-Efficiency Liquid Desiccant Regenerator for Desiccant Enhanced Evaporative Air Conditioning
SBIR 第一阶段:用于干燥剂增强蒸发空调的高效液体干燥剂再生器
  • 批准号:
    2335500
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    Standard Grant
Catalyzing Sustainable Air Travel: Unveiling Consumer Willingness to Pay for Sustainable Aviation Fuel through Information Treatment in Choice Experiment and Cross-Country Analysis
促进可持续航空旅行:通过选择实验和跨国分析中的信息处理揭示消费者支付可持续航空燃油的意愿
  • 批准号:
    24K16365
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
COMPAS: co integration of microelectronics and photonics for air and water sensors
COMPAS:微电子学和光子学的共同集成,用于空气和水传感器
  • 批准号:
    10108154
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    EU-Funded
Simulating Urban Air Pollution In The Lab
在实验室模拟城市空气污染
  • 批准号:
    MR/Y020014/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    Fellowship
Collaborative Research: Phenotypic and lineage diversification after key innovation(s): multiple evolutionary pathways to air-breathing in labyrinth fishes and their allies
合作研究:关键创新后的表型和谱系多样化:迷宫鱼及其盟友呼吸空气的多种进化途径
  • 批准号:
    2333683
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    Continuing Grant
Collaborative Research: Phenotypic and lineage diversification after key innovation(s): multiple evolutionary pathways to air-breathing in labyrinth fishes and their allies
合作研究:关键创新后的表型和谱系多样化:迷宫鱼及其盟友呼吸空气的多种进化途径
  • 批准号:
    2333684
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    Continuing Grant
CRII: CSR: Towards an Edge-enabled Software-Defined Vehicle Framework for Dynamic Over-the-Air Updates
CRII:CSR:迈向支持边缘的软件定义车辆框架,用于动态无线更新
  • 批准号:
    2348151
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    Standard Grant
Development of a low-pressure loss air purification device using rotating porous media and a proposal for its use in ventilation systems
使用旋转多孔介质的低压损失空气净化装置的开发及其在通风系统中的使用建议
  • 批准号:
    24K17404
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
  • 批准号:
    10100997
  • 财政年份:
    2024
  • 资助金额:
    $ 35.96万
  • 项目类别:
    EU-Funded
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了